EPISODE · Dec 28, 2025 · 28 MIN
Collagen stimulators, clinical standards, and the regulatory maze
from HealthCert Insights – A Podcast for Doctors, Nurses and Healthcare Professionals · host HealthCert Education
In this episode of HealthCert's The Aesthetic Shift podcast series, Kelly Beasy sits down with Naomi Grayson — registered nurse, educator, and co-founder of Pinkit Medical — to explore the evolving world of regenerative aesthetics. Naomi shares how her clinical background shaped the development of collagen-stimulating treatments, why skin quality is becoming central to modern aesthetic practice, and what clinicians should understand about choosing and using these products safely. This episode also touches on the often-misunderstood regulatory landscape in Australia, including how topical products differ from TGA-regulated medicines, what clinicians should be checking before introducing a new product, and why transparency from suppliers matters more than ever. If you are curious about where collagen stimulators fit into contemporary practice, how practitioners can approach education and product selection with rigour, or what the industry shift toward skin-focused treatments means for clinics, this conversation is worth a listen. Watch this episode here. Next steps in your learning journey 🎓 Micro-Courses in Aesthetic Medicine Explore short, bite-sized CPD modules in focused topics in cosmetic medicine for GPs and nurses. Complete in less than 10 hours. ➡️ Browse Micro-Courses > 🎓 Certificate Courses in Aesthetic Medicine Explore our university-assured, structured Professional Diploma pathway to elevate your skills in primary care cosmetic medicine. ➡️ Explore full program >
What this episode covers
Kelly Beasy and RN Naomi share insights on collagen stimulators, skin quality treatments, and the TGA regulatory landscape.
NOW PLAYING
Collagen stimulators, clinical standards, and the regulatory maze
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m